Uripay Tablet 100 mg

Uripay Tablet 100 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Uripay Tablet 100 mg
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Uripay Tablet 100 mg
Generic	Flavoxate Hydrochloride
Weight	100 mg
Type	Tablet
Therapeutic Class	BPH/ Urinary retention/ Urinary incontinence
Manufacturer	Al-Madina Pharmaceuticals Ltd.
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Flavoxate is indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis and urethrocystitis.

Dosage

Uripay Tablet 100 mg dosage

Adults and children over 12 years of age: 100 mg to 200 mg 3 times a day. With improvement of symptoms, the dose may be reduced.Pediatric Use: Safety and effectiveness in children below the age of 12 years have not been established.

Side Effects

Gastrointestinal: Nausea, vomiting, dry mouth.CNS: Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.Hematologic: Leukopenia (which is reversible upon discontinuation of the drug).Cardiovascular: Tachycardia and palpitation.Allergic: Urticaria and other dermatoses, eosinophilia and hyperpyrexia.Ophthalmic: Increased ocular tension, blurred vision, disturbance in eye accommodation.

Precaution

Flavoxate should be given cautiously in patients with suspected glaucoma

Pregnancy & Breastfeeding use

Pregnancy: Pregnancy Category B. This drug should be used during pregnancy only if clearly needed.Nursing Mothers: It is not known whether this drug is excreted in human milk. Caution should be exercised when flavoxate is administered to a nursing woman.

Contraindication

Flavoxate is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.